antibiotic efflux: from discovery to epidemiological ... · antibiotic efflux: from discovery to...

of 38 /38
14-2-2012 Tours-INRA 1 Antibiotic efflux: from discovery to Antibiotic efflux: from discovery to epidemiological, clinical, and veterinary impact epidemiological, clinical, and veterinary impact Françoise Van Bambeke & Paul M. Tulkens Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université catholique de Louvain, Brussels, Belgium <www.facm.ucl.ac.be>

Author: others

Post on 11-Jan-2020

11 views

Category:

Documents


2 download

Embed Size (px)

TRANSCRIPT

  • 14-2-2012 Tours-INRA 1

    Antibiotic efflux: from discovery to Antibiotic efflux: from discovery to epidemiological, clinical, and veterinary impactepidemiological, clinical, and veterinary impact

    Françoise

    Van Bambeke & Paul M. Tulkens

    Pharmacologie cellulaire et moléculaireLouvain Drug Research

    InstituteUniversité

    catholique de Louvain, Brussels, Belgium

  • 14-2-2012 Tours-INRA 2

    DiscoveryDiscovery

    and and significancesignificance

    ……..

  • 14-2-2012 Tours-INRA 3

    Chemotherapeutic

    agents exert

    toxic

    effects on specific

    target

    cells

    antifungals

    anticancer

    agents

    antibiotics

  • 14-2-2012 Tours-INRA 4

    Chemotherapeutic

    agents exert

    toxic

    effects on specific

    target

    cells

    How can

    these

    drugsreach

    their

    target

    inside

    the cells

    ?

    nucleic

    acids

    ribosomes

    enzymes

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 5

    Reaching

    an intracellular

    target

    polar drug

    lipophilic

    drug

    physico-chemical properties are inadequate for reaching an intracellular target !

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 6

    Reaching

    an intracellular

    target

    amphipathic

    drug

    most drugs are amphipathic

    by design,to be able to cross membrane barriers !

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 7

    Intracellular

    chemotherapeutic

    agents

    But a diffusible compound may have

    potentially harmful effects !Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 8

    Why

    efflux transporters

    ?

    Extrusion by efflux pumps

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 9

    Why

    efflux transporters

    ?

    Extrusion by efflux pumps

    general mean of protectionagainst cell invasion by diffusible molecules

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 10

    Most antibiotics

    are amphiphilic

    !

    macrolide tetracycline

    fluoroquinolone

    rifampicin

    sulfamide

    lincosamide

    +

    +

    ++

    +

    +cationic amphiphiles

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 11

    Most antibiotics

    are amphiphilic

    !

    fluoroquinolone

    -lactam

    fusidic

    acid

    -

    -

    -

    anionic

    amphiphiles

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 12

    Antibiotic

    efflux transporters

    are ubiquituous

    spectrumprokaryotes

    narrow

    broad

    MATE SMR

    MFS

    ABC

    Gram (+) Gram (-)

    RND

    distribution

    eukaryotes

    Mesaros

    et al. (2005) Louvain médical. 124:308-20

  • 14-2-2012 Tours-INRA 13

    Antibiotics

    as substrates

    of efflux pumps

    Antibiotic bacteria

    fungi

    superiorclass Gram (+) Gram(-)

    eucaryotes

    -lactamsfusidic

    acidmacrolidesstreptograminstetracyclinesaminoglycosideschloramphenicolrifamycinssulfamidestrimethoprimfluoroquinolones

    Van Bambeke

    et al. (2000) Biochem. Pharmacol. 60:457-70

  • 14-2-2012 Tours-INRA 14

    Antibiotic

    efflux and resistance: time line …

    tetracy

    clines

    1980

    1990

    2000

    macro

    lides

    fluoroq

    uinolo

    nes

    Beta-la

    ctame

    s

    amino

    glycos

    ides

    chlora

    mphen

    icol

    rifamp

    inoxa

    zolidin

    ones

  • 14-2-2012 Tours-INRA 15

    Efflux as a mechanism

    of export in antibiotic

    producers

    spectrum

    narrow

    broad

    specific

    for the produced

    antibiotic

    ABC MFS

    Ptr

    of S. pristinaespiralis pristinamycinLmrA

    of S. lincolnensis lincomycinRifP

    of A. mediterranei rifampicin

    OleB

    or C of S. antibioticus oleandomycinSmB

    of S. ambofaciens macrolidesTlrc

    of S. fradiae tylosin

  • 14-2-2012 Tours-INRA 16

    Efflux as a mechanism

    of resistance in Gram-positive bacteria

    spectrum

    narrow

    broad

    specific

    for one (or a few) families

    of drugs

    ABC MFS

    NorA

    of S. aureus FQ,Tet, chlMefE

    of S. pneumoniae MLPmrA

    of S. pneumoniae FQMefA

    of S. pyogenes ML

    PatA/PatB

    of S. pneumoniae FQ, chlMsrA

    of S. epidermidis erythromycin

  • 14-2-2012 Tours-INRA 17

    FQ efflux pumps

    in S. pneumoniae

    Terry et al., Nature Reviews Microbiology

    2005; 3:

    566-572

    Primary

    transporters«

    ATP-Binding

    Cassette

    »

    Secondary

    transporters(Proton motive force)

    PmrAGill et al, AAC 1999; 43:187-9

    PatA/PatBMarrer et al, AAC 2006; 50:685-93

  • 14-2-2012 Tours-INRA 18

    Efflux as a mechanism

    of resistance in Gram-negative

    bacteria

    spectrum

    narrow

    broad

    broad

    spectrum, conferring

    cross-resistance

    MFS

    RNDMexAB-OprM

    of P. aeruginosa -lac, FQ,Tet, ML, chl, rif, sulfAcrAB-TolC

    of E. coli -lac,

    FQ,Tet, ML, chl, rif, sulf

    TetA

    of E. coliTetMsrA

    of S. epidermidis erythromycin

    specific

    for one (or a few) families

    of drugs

  • 14-2-2012 Tours-INRA 19

    Efflux and resistance in P. aeruginosa

    Mesaros

    et al. (2005) Louvain médical. 124:308-20

    MexB

    MexA

    OprM

    MexY

    MexX

    OprM

    MexD

    MexC

    OprJ

    MexF

    MexE

    OprN

    Constitutive

    basal expressionoverexpressed

    upon

    induction

    No basal expression;expression

    upon

    induction

  • 14-2-2012 Tours-INRA 20

    RoleRole

    of of antibioticantibiotic

    efflux efflux in in epidemiologyepidemiology

    and and resistanceresistance

    ……..

  • 14-2-2012 Tours-INRA 21

    Does

    efflux mean

    «

    resistance

    »

    vs. epidemiological

    breakpoints

    ?

    MICs

    vs breakpoints

    for 183 S. pneumoniae

    isolated

    from

    CAP

    Lismond

    et al., JAC (2011) 66:948-951

    Efflux (+) strains

    consideredas susceptible

    FQ with

    high

    intrinsic

    activity

    can

    be

    substrates

    for efflux !

  • 14-2-2012 Tours-INRA 22

    Does

    efflux mean

    «

    resistance

    »

    vs. epidemiological

    breakpoints

    ?

    MICs

    vs EUCAST breakpoints

    for 109 P. aeruginosa

    without

    or with

    efflux mechanisms,

    isolated

    from

    ICU patients (VAP)

    Riou

    et al, ECCMID 2010

    meropenem

    mexA < 2 mexA 20.03125

    0.06250.125

    0.250.5

    1248

    163264

    128256

    mexA expression level

    amikacin

    mexX < 5 mexX 50.25

    0.51248

    163264

    128256

    mexX expression level

    MIC

    pip-tazo

    mexA < 2 mexA 20.03125

    0.06250.125

    0.250.5

    1248

    163264

    128256

    mexA expression level

    MexXsubs

    tr.

    MexAsubs

    tr.

    MexAsubs

    tr.

  • 14-2-2012 Tours-INRA 23

    Efflux and intrinsic

    resistance

    Is Pseudomonas

    «

    intrinsically

    »

    resistant

    to temocillin

    ?

    Buyck

    et al, J. Antimicrob. Chemother. (2012) 67(3):771-5

    MexAB-OprM

    mutants are highly

    susceptible!

  • 14-2-2012 Tours-INRA 24

    Efflux and intrinsic

    resistance

    Is Pseudomonas

    «

    intrinsically

    »

    resistant

    to macrolides ?

    Buyck

    et al, ICAAC (2011)

    0.25 0.5 1 2 4 8 16 32 64 128

    256

    512

    1024

    0

    25

    50

    75

    100MHB-OprM(+)MHB-OprM(-)

    MIC (mg/L)

    cum

    ulat

    ive

    perc

    enta

    ge

    Major role

    of constitutively-expressed

    transporters!

  • 14-2-2012 Tours-INRA 25

    RoleRole

    of efflux of efflux pumpspumps

    in the in the clinicsclinics

    ……

  • 14-2-2012 Tours-INRA 26

    FQ resistance

    by efflux in S. pneumoniae is

    mediated

    by PatA/PatB

    FQstrains

    CIP MXF-Res +Res -R +R

    49619 1 0.5 0.125 0.125

    patA 0.5 0.5 0.125 0.125

    patB 0.5 0.5 0.125 0.125

    pmrA 1 0.5 0.125 0.125

    SP335 32 2 0.5 0.25

    patA 1 0.5 0.125 0.125

    patB 1 0.5 0.125 0.125

    pmrA 8 0.5 0.25 0.125

    CIP affected

    but not MXF !

  • 14-2-2012 Tours-INRA 27

    FQ induce

    efflux, whether

    substrates

    or not

    Both

    CIP and MXF are inducers

    !

    El Garch

    et al., JAC

    (2010)

    65:2076-82

  • 14-2-2012 Tours-INRA 28

    Selection

    of resistance

    in S. pneumoniae by subMIC

    concentrations of FQ

    ciprofloxacin moxifloxacin

    Avrain

    et al, JAC (2007) 60:965-972

    no efflux

    basal efflux

    Ciprofloxacin

    selects for resistance

    by efflux

  • 14-2-2012 Tours-INRA 29

    Selection

    of resistance

    in S. pneumoniae by subMIC

    concentrations of FQ

    moxifloxacin

    Avrain

    et al, JAC (2007) 60:965-972

    no efflux

    basal efflux

    Moxifloxacin

    selects for resistance

    by target

    mutation(topoisomerases)

    GyrA

    (Ser81Phe)ParC

    (Ser79Tyr)

    ParE

    (Ile460Val)ParE

    (Arg447Cys)

  • 14-2-2012 Tours-INRA 30

    Efflux in

    S. pneumoniae: is

    it

    important in the clinics

    ?

    Suspected

    efflux based

    on phenotypic

    analysis

    (CIP MIC +/-

    reserpine)

    CAP BPCO0

    20

    40

    60

    80

    100 1 2 2

    reserpine effect on MIC (x dilutions)

    origin of isolates

    % s

    trai

    ns

    Lismond

    & Degives, unpublished

    acute pathology

    «

    one shot

    »antibiotic

    exposure

    chronic

    pathology

    repetitiveantibiotic

    exposures

    183 strains 107 strains

  • 14-2-2012 Tours-INRA 31

    Efflux in

    P. aeruginosa: is it important in the clinics ?

    Prevalence of MexA

    and MexX

    overexpressers

    in 62 phylogentically-related pairs of P. aeruginosa

    isolated from ICU patients (VAP)

    DAY x (%)

    38.71%

    22.58%

    20.97%

    17.74%

    DAY 0 (%)

    66.13%

    12.90%

    11.29%

    9.68%

    MexA-/MexX-

    MexA+/MexX-

    MexX+/MexA-

    MexA+/MexX+

    Riou

    et al, ECCMID 2010

  • 14-2-2012 Tours-INRA 32

    Efflux selection in

    P. aeruginosa

    during treatment

    Riou

    et al, ECCMID 2010

    Antibiotic no. patients

    Piperacillin-tazobactam

    (TZP) 26Amikacin

    (AMK) 22Meropenem

    (MEM) 20Cefepime

    (CEF) 19Ciprofloxacin (CIP) 6

    Antipseudomonal

    antibiotics received by the patients during

    treatment

    DAY 0 DAY X05

    1015

    202530

    3540

    455055

    60

    0

    234

    1

    nb effluxsystems

    num

    ber o

    f str

    ains

    global influence of treatment

    number of efflux systems detected at day 0 and day X

    69% com

    binations

  • 14-2-2012 Tours-INRA 33

    And in And in veterinaryveterinary

    practice ?practice ?

  • 14-2-2012 Tours-INRA 34

    Efflux and resistance

    Efflux involved

    in intrinsic

    resistance

    and low

    level

    resistance

  • 14-2-2012 Tours-INRA 35

    Risks

    of cross-contamination!

    Efflux system

  • 14-2-2012 Tours-INRA 36

    Antibiotics

    as inhibitors

    of efflux

    Tetracyclines

    as inhibitors

    of efflux

  • 14-2-2012 Tours-INRA 37

    Efflux and Efflux and bacteriabacteria

    in in ourour

    team team ……

    www.facm.ucl.ac.be

    GRAM(+)

    GRAM(-)

    L. Avrain M. Riou J. Buyck A. Anantharajah

    F. el Garch C. Vallet A. Lismond F. Degives

    V. Mohymont

  • 14-2-2012 Tours-INRA 38

    Les aventures dLes aventures d’’un Tourangeauun Tourangeau àà

    Bruxelles Bruxelles ……

    Appliqué

    à

    suivre les travaux pratiques des étudiants …

    … et à

    tester la gastronomie locale !

    Antibiotic efflux: from discovery to �epidemiological, clinical, and veterinary impactDiscovery and significance ….Chemotherapeutic agents exert toxic effects�on specific target cellsChemotherapeutic agents exert toxic effects�on specific target cellsReaching an intracellular target …Reaching an intracellular target …Intracellular chemotherapeutic agentsWhy efflux transporters ?Why efflux transporters ?Most antibiotics are amphiphilic !Most antibiotics are amphiphilic !Antibiotic efflux transporters are ubiquituousAntibiotics as substrates of efflux pumpsAntibiotic efflux and resistance: time line …Efflux as a mechanism of export �in antibiotic producersEfflux as a mechanism of resistance�in Gram-positive bacteriaFQ efflux pumps in S. pneumoniaeEfflux as a mechanism of resistance �in Gram-negative bacteriaEfflux and resistance in P. aeruginosaRole of antibiotic efflux �in epidemiology and resistance ….Does efflux mean « resistance » vs. epidemiological breakpoints ?Does efflux mean « resistance » vs. epidemiological breakpoints ?Efflux and intrinsic resistanceEfflux and intrinsic resistanceRole of efflux pumps in the clinics …FQ resistance by efflux in S. pneumoniae �is mediated by PatA/PatB FQ induce efflux, whether substrates or not Selection of resistance in S. pneumoniae �by subMIC concentrations of FQSelection of resistance in S. pneumoniae �by subMIC concentrations of FQEfflux in S. pneumoniae: �is it important in the clinics ?Efflux in P. aeruginosa:�is it important in the clinics ?Efflux selection in P. aeruginosa during treatmentAnd in veterinary practice ?Efflux and resistanceRisks of cross-contamination!Antibiotics as inhibitors of effluxEfflux and bacteria in our team … Les aventures d’un Tourangeau�à Bruxelles …